Leukemia Clinical Trial
Official title:
A Phase I/II Dose-Finding Study to Determine the Safety, Tolerability, and Anti-Leukemic Effects of STI571 (NSC 716051) in Combination With Interferon-alpha in Patients With Chronic Myelogenous Leukemia in Chronic Phase
RATIONALE: Imatinib mesylate and interferon alfa may interfere with the growth of the cancer
cells. Combining imatinib mesylate with interferon alfa may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining imatinib mesylate with
interferon alfa in treating patients who have chronic myelogenous leukemia.
OBJECTIVES:
- Determine the maximum tolerated dose of interferon alfa administered with imatinib
mesylate in patients with chronic phase chronic myelogenous leukemia. (Phase I closed
to accrual as of 7/9/03.)
- Determine the safety and tolerability of this regimen in this patient population.
- Determine the complete, major, and minor cytogenetic response rates and complete
hematologic response rate in patients after 6 and 12 months of treatment with this
regimen.
- Determine the molecular response (reverse transcriptase-polymerase chain reaction for
bcr-abl) rate in patients who have a complete cytogenetic response after 6 and 12
months of treatment with this regimen.
- Determine the pharmacokinetics of this regimen in these patients.
OUTLINE: This is a dose-escalation, multicenter study.
- Phase I (closed to accrual as of 7/9/03): Patients receive oral imatinib mesylate once
daily beginning on day 1 and interferon alfa (IFN-A) subcutaneously once daily or 3
times weekly beginning on day 14. Courses repeat every 35 days for up to 1 year in the
absence of disease progression or unacceptable toxicity. After completion of 1 year of
therapy, patients may receive additional therapy, provided that the patient is
benefiting from imatinib mesylate. IFN-A is discontinued in patients who achieve a
molecular remission that is confirmed on 2 successive bone marrow samples. Imatinib
mesylate is discontinued in patients who achieve and maintain a molecular remission for
2 years.
Sequential dose escalation of IFN-A is followed by sequential dose escalation of imatinib
mesylate. Cohorts of 3-6 patients receive escalating doses of IFN-A and then imatinib
mesylate until the maximum tolerated dose (MTD) of the combination is determined. The MTD is
defined as the dose preceding that at which 2 of 6 patients experience dose-limiting
toxicity.
- Phase II: Patients receive imatinib mesylate and IFN-A as in phase I at the established
MTD.
Patients are followed for 30 days.
PROJECTED ACCRUAL: Approximately 3-15 patients will be accrued for the phase I portion of
this study. (Phase I closed to accrual as of 7/9/03.) A total of 40 patients will be accrued
for the phase II portion of the study within 3-4 months.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
| Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
| Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
| Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
| Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
| Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
| Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
| Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
| Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |